Aims. The aim of this study was to establish p53 immunohistochemistry (IHC) patterns to
predict TP53 mutations in gastrointestinal neuroendocrine neoplasms (GI‐NENs) and to …

Background Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are
aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy …

Background Chemotherapy has limited efficacy in advanced digestive high-grade
neuroendocrine neoplasms (HG-NEN) and prognosis is dismal. Predictive markers for …

Background: In gastroenteropancreatic (GEP) high-grade neuroendocrine neoplasms (H-
NENs), Ki-67 threshold of 55% defines three prognosis subclasses: neuroendocrine tumor …

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are heterogeneous and
especially the midgut tumors currently lack effective therapy options. Actionable driver …

Background: The rarity of neuroendocrine malignancies limits the ability to develop new
therapies and thus a better understanding of the underlying biology is critical. Methods …

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare epithelial
neoplasms. Grading is based on mitotic activity or the percentage of Ki67-positive cells in a …

ABSTRACT Background/Aims: Gastrointestinal and pancreatic neuroendocrine tumors
(GEPNETs) originate from the cells of the endocrine system. Their molecular genetic …

Gastric neuroendocrine carcinoma (NEC) is a rare tumor with a poor prognosis. Due to its
rarity and disparity in prevalence across populations, there is limited data on gastric NEC …

Rectal neuroendocrine tumors (NETs) are the most common gastrointestinal (GI) NETs with
an uncertain malignant potential despite their small size. There are limited data about driver …